Kim LufkinGHTC
Kim Lufkin is a communications officer at GHTC.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
Results from a study published in the Lancet and presented at the XIX International AIDS Conference indicate that a novel tuberculosis combination drug may be on the horizon.
The World Health Organization has endorsed the use of the antiretroviral drug Truvada for HIV prevention among HIV-negative people considered at a high risk.
The US Food and Drug Administration has granted fast-track designation for Idenix Pharmaceuticals' drug candidate to treat hepatitis C.
Drug maker Sanofi said its experimental vaccine against dengue fever proved safe and effective in a study in 4,000 children in Thailand, raising prospects for the first-ever vaccine against the disease after decades of research.
The results of scientific research that addresses global health diseases and other issues will become freely available as part of the UK government's plans to open up access to publicly funded studies.